CNS spectrumsHumansKetamineMaleFemaleMajor Depressive Disorder
Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the depTesk (DEPression treatment with ESKetamine) study.
Ana Rodríguez Lorente, María Pilar Campos-Navarro, Ángela Gil Montoya, Celia Marín Pérez, María Luisa Maso Navarro, Tomás Orgaz Morales, Nuria López Ramirez, Juan Antonio García-Carmona
Published: 202510.1017/S1092852925100631
Abstract
OBJECTIVES: This proof-of-concept study aimed to assess the impact of intranasal esketamine (ESK-IN) in brain volume and neurofilament light chain (sNfL) over 6-months in patients with treatment resistant depression (TDR). METHODS: Seven TRD patients…
Preview only. Read the full abstract at the source